Your browser doesn't support javascript.
loading
CD226 Throttles up CD8+ T Cell Antitumor Activity.
Philip, Mary.
Afiliação
  • Philip M; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address: mary.philip@vumc.org.
Immunity ; 53(4): 704-706, 2020 10 13.
Article em En | MEDLINE | ID: mdl-33053327
In this issue of Immunity, Weulersse et al. and Braun et al. explain how CD226 expression loss on CD8+ T cells impairs TCR-driven activation, and thereby anti-tumor effector responses, tantamount to taking the CD8+ T cell's foot off the gas pedal.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article